DUBLIN, June 27,
2022 /CNW/ -- Medtronic plc (NYSE: MDT) today
announced that its Board of Directors appointed Lidia Fonseca, Executive Vice President, Chief
Digital and Technology Officer at Pfizer, to the Board as an
independent director, effective June 27,
2022. Ms. Fonseca will serve on the Compensation Committee
and Science and Technology Committee of the Board.
"We are thrilled to welcome Lidia to Medtronic's Board of
Directors," said Geoff Martha,
Medtronic chairman and chief executive officer. "She has an
impressive history of developing digital healthcare solutions that
deliver powerful insights to improve patients' lives. Her extensive
knowledge and expertise will provide the Board with an important
dimension and a tremendously valuable perspective as we drive
toward our bold ambition to become the global leader in healthcare
technology."
Ms. Fonseca has more than 30 years of experience in healthcare
innovation. In her current role, she is responsible for developing
and implementing an enterprise-wide digital strategy, leading all
digital, data and technology solutions across the company. She is
also responsible for Pfizer Learning and Development and Business
Process Excellence.
Ms. Fonseca also spearheads several innovative programs and
initiatives, including those that digitize drug discovery and
development; improve health outcomes and patient experiences
through digital health, medicines, and diagnostics; advance
operational processes through automation and robotics; and deliver
powerful insights with advanced analytics and artificial
intelligence (AI) for better decision-making.
Most recently, she led Pfizer's digital team as the company made
critical efforts to help accelerate the development of a COVID-19
vaccine in less than a year. She also led the efforts to create
Pfizer's Advanced Analytics Platform that combines data and tools
from Pfizer and its external partners to model scientific and
clinical decisions, patterns, and insights.
Prior to her current role, from 2014 to 2018, Ms. Fonseca was
the Senior Vice President and CIO at Quest Diagnostics, the world's
leading provider of diagnostic information services, where she was
responsible for technology, informatics, and digital solutions.
Prior to that she served as the Senior Vice President and Chief
Information Officer at Labcorp from 2008 to 2013.
Throughout her career, Ms. Fonseca has received several awards
and accolades, including being named on the 2022 Forbes CIO Next
List recognizing the top 50 tech leaders who are redefining the CIO
role and driving game-changing innovation. She was recognized
as one of the 50 Most Powerful Latinas in 2020 and 2021 by the
Association of Latino Professionals for America, as well as a 2020
Healthcare Influencer and 2019 Healthcare Transformer by Medical,
Marketing & Media. She has received the Forbes CIO Innovation
Award in 2017 and currently serves on the U.S.-Japan Business
Council.
About Medtronic
Bold thinking. Bolder actions. We are
Medtronic. Medtronic plc, headquartered in Dublin, Ireland, is the leading global
healthcare technology company that boldly attacks the most
challenging health problems facing humanity by searching out and
finding solutions. Our Mission — to alleviate pain, restore health,
and extend life — unites a global team of 95,000+ passionate people
across 150 countries. Our technologies and therapies treat 70
health conditions and include cardiac devices, surgical robotics,
insulin pumps, surgical tools, patient monitoring systems, and
more. Powered by our diverse knowledge, insatiable curiosity, and
desire to help all those who need it, we deliver innovative
technologies that transform the lives of two people every second,
every hour, every day. Expect more from us as we empower
insight-driven care, experiences that put people first, and better
outcomes for our world. In everything we do, we are engineering the
extraordinary. For more information on Medtronic (NYSE: MDT), visit
www.Medtronic.com and follow @Medtronic on Twitter and
LinkedIn.
Any forward-looking statements are subject to risks and
uncertainties such as those described in Medtronic's periodic
reports on file with the Securities and Exchange Commission. Actual
results may differ materially from anticipated results.
Contacts:
|
|
|
|
Erika
Winkels
|
Ryan
Weispfenning
|
Public
Relations
|
Investor
Relations
|
+1-763-526-8478
|
+1-763-505-4626
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/medtronic-board-appoints-lidia-fonseca-as-a-new-director-301575429.html
SOURCE Medtronic plc